Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?

Medical Microbiology and Immunology

Volumn 204, Issue 1, 2015, Pages 121-129

  Michel, Marie Louise ^a   Bourgine, Maryline ^a   Fontaine, Hélène ^b,c   Pol, Stanislas ^a,b,c  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

Chronic infection; Clinical trial; DNA vaccine; Hepatitis B; Immune therapy; T cell therapy; Vaccine

Indexed keywords

ADEFOVIR; DNA VACCINE; GS 4774; GS 9620; HB 110; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LAMIVUDINE; NUCLEOSIDE ANALOG; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; HEPATITIS B VACCINE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIBODY DETECTION; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; DISEASE COURSE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; VIRAL TROPISM; VIRUS DETECTION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; CLINICAL TRIAL (TOPIC); HEPATITIS B, CHRONIC; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84925501250     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-014-0381-y     Document Type: Review

References (68)

1. Ganem D, Prince AM (2004) Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 350:1118–1129
2. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359:1486–1500
3. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50:661–662
4. Chen DS (2009) Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 50:805–816
5. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M et al (2011) Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54:801–807
6. European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167–185
7. Pol S, Lampertico P (2012) First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat 19:377–386
8. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y et al (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98–107
9. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(1593–1608):e1591–e1592
10. Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65–91
11. Rehermann B, Nascimbeni M (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5:215–229
12. Rehermann B (2007) Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 27:152–160
13. + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78:5707–5719
14. Rehermann B, Lau D, Hoofnagle JH, Chisari FV (1996) Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97:1655–1665
15. Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG et al (2002) Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122:614–624
16. Maini MK, Schurich A (2010) The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 52:616–619
17. Michel ML, Deng Q, Mancini-Bourgine M (2011) Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 54:1286–1296
18. Pol S, Driss F, Michel M-L, Nalpas B, Berthelot P et al (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342
19. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P et al (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34:917–921
20. Couillin I, Pol S, Mancini M, Driss F, Brechot C et al (1999) Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180:15–26
21. Pol S, Michel ML (2006) Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 5:707–716
22. Wen YM (2009) Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin Biol Ther 9:285–291
23. Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q et al (2008) A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 3:e2565
24. Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H et al (2013) Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59:450–456
25. Wang XY, Yao X, Wan YM, Wang B, Xu JQ et al (2013) Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice. Immunol Lett 149:88–92
26. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillen G et al (2005) Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 42:289–294
27. Betancourt AA, Delgado CA, Estevez ZC, Martinez JC, Rios GV et al (2007) Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 11:394–401
28. Akbar SM, Al-Mahtab M, Rahman S, Aguilar JC, Onji M et al (2010) A therapeutic nasal vaccine combining both HBsAg and HBcAg wassafe, has antiviral potential and induced antigen-specific immunity in patients with chronic hepatitis B. Hepatol Int 4:159
29. Al-Mahtab M, Akbar SM, Aguilar JC, Uddin H, Khan SI et al (2013) Therapeutic potential of a combined HBsAg and HBcAg vaccine in patients with chronic hepatitis B. Hepatol Int 7:981–989
30. Al-Mahtab M, Akbar F, Uddin H, Rahman S, Aguilar Rubido JC et al (2013) A phase III clinical trial with a nasal vaccine containing both HBsAg and HBcAg in patients with chronic Hepatitis B. J Hepatol 58:S229–S407
31. Mueller SN, Ahmed R (2009) High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 106:8623–8628
32. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I et al (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39:595–605
33. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M et al (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963–971
34. Alatrakchi N, Koziel MJ (2003) Antiviral T-cell responses and therapy in chronic hepatitis B. J Hepatol 39:631–634
35. + T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20:3598–3612
36. Hoa PT, Huy NT, le Thu T, Nga CN, Nakao K et al (2009) Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 53:5134–5140
37. Horiike N, Fazle Akbar SM, Michitaka K, Joukou K, Yamamoto K et al (2005) In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 32:156–161
38. Vandepapeliere P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E et al (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585–8597
39. Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ (1997) Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 314:329–333
40. Bourgine M, Dion S, Godon O, Guillen G, Michel ML et al (2012) Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model. Virology 430:10–19
41. Mansour-Ghanaei F, Joukar F, Khalili D, Valeshabad AK (2012) Efficacy of double dose intradermal vaccination in chronic hepatitis B carriers: a double-blinded randomized clinical trial. J Vaccin Vaccin 3:140
42. Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175:633–639
43. Loirat D, Lemonnier FA, Michel ML (2000) Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 165:4748–4755
44. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K et al (2013) Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 4:354–363
45. Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML (2006) Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24:4482–4489
46. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C et al (2004) Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40:874–882
47. Scott-Algara D, Mancini-Bourgine M, Fontaine H, Pol S, Michel ML (2010) Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS ONE 5:e8761
48. Godon O, Fontaine H, Kahi S, Meritet J, Scott-Algara D et al (2014) Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther 22:675–684
49. Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, et al (2015) Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial–ANRS HB02 VAC-ADN. Gut 64(1):139–147
50. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E (2012) Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 143(629–636):e621
51. Yang FQ, Yu YY, Wang GQ, Chen J, Li JH et al (2012) A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 19:581–593
52. Yang SH, Lee CG, Park SH, Im SJ, Kim YM et al (2006) Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 13:1110–1117
53. Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S et al (2005) Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 42:1028–1036
54. Im SJ, Yang SH, Yoon SK, Sung YC (2009) Increase of plasma IL-12/p40 ratio induced by the combined therapy of DNA vaccine and lamivudine correlates with sustained viremia control in CHB carriers. Immune Netw 9:20–26
55. Kim CY, Kang ES, Kim SB, Kim HE, Choi JH et al (2008) Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med 40:669–676
56. Yoon SK, Seo YB, Im SJ, Bae SH, Song MJ, et al (2014) Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int. doi:10.1111/liv.12530
57. Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H et al (2011) Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS ONE 6:e14626
58. Inchauspe G, Michel ML (2007) Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat 14(Suppl 1):97–103
59. Liu J, Zhang E, Ma Z, Wu W, Kosinska A et al (2014) Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 10:e1003856
60. King TH, Kemmler CB, Guo Z, Mann D, Lu Y et al (2014) A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS ONE 9:e101904
61. Gaggar A, Coeshott C, Apelian D, Rodell T, Armstrong BR et al (2014) Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 32:4925–4931
62. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, et al (2013) GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144:1508–1517, 1517 e1501–e1510
63. Bergmann JF, de Bruijne J, Hotho DM, de Knegt RJ, Boonstra A et al (2011) Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 34:443–453
64. Lopatin U, Wolfgang G, Tumas D, Frey CR, Ohmstede C et al (2013) Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther 18:409–418
65. Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M et al (2012) Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143(963–973):e969
66. Bertoletti A, Ferrari C (2012) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61:1754–1764
67. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
68. + T lymphocytes in the liver. J Immunol 178:2714–2720